Concepedia

Lola A. Fashoyin‐Aje

LA

37

Publications

2.9K

Citations

25

H-Index

2012

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Johnson & Johnson (United States)

Janssen (United States)

National Cancer Institute

Lola A. Fashoyin‐Aje is an author at United States Food and Drug Administration specializing in medicine, clinical trials, and oncology.

ORCID

Top concepts

Publications per year

2012–2024

37

Publications

37

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue et al. · Clinical Cancer Research · 2021 · 532 citations · Full text

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement

Randall A. Oyer, Patricia A. Hurley, Leigh Boehmer et al. · Journal of Clinical Oncology · 2022 · 228 citations

, , +26

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1

Lola A. Fashoyin‐Aje, Martha Donoghue, Huanyu Chen et al. · The Oncologist · 2018 · 224 citations · Full text

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2020 · 170 citations

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2021 · 167 citations · Full text

Rows per page

1–5 of 37